Significance of AKT in gastric cancer (review)

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2187-2192

  Sasaki, Takamitsu ^a   Kuniyasu, Hiroki ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

AKT; Gastric cancer; Human telomerase reverse transcriptase

Indexed keywords

ONCOPROTEIN; TUMOR PROTEIN;

BIOSYNTHESIS; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR INVASION;

CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84907680968     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2678     Document Type: Review

References (32)

1. Tokunaga E, Oki E, Egashira A, Sadanaga N, et al: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8:27-36, 2008.
2. Stiles B, Gilman V, Khanzenzon N, et al: Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22:3842-3851, 2002.
3. Bellacosa A, Testa JR, Moore R and Larue L: A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 3:268-275, 2004.
4. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129:1261-1274, 2007.
5. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619, 2006.
6. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501, 2002.
7. Sukawa Y, Yamamoto H, Nosho K, et al: Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-A kt pathway in gastric cancer. World J Gastroenterol 18:6577-6586, 2012.
8. Berg M and Soreide K: EGFR and downstream genetic alterations in KRA S/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 14:207-214, 2012.
9. Ng L, Poon RT and Pang R: Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 70:3631-3656, 2013.
10. Cheung M and Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 13:234-244, 2013.
11. Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15:177-182, 2004.
12. Radisavljevic Z: AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol 228:21-24, 2013.
13. Xu M and Mo YY: The Akt-associated microRNA s. Cell Mol Life Sci 69:3601-3612, 2012.
14. Park BK, Zeng X and Glazer RI: Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61:7647-7653, 2001.
15. Kim D, Kim S, Koh H, et al: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FA SEB J 15:1953-1962, 2001.
16. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH and Testa JR: AKT activation up-regulates insulin-like growth factor-I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61:589-593, 2001.
17. Grille SJ, Bellacosa A, Upson J, et al: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63:2172-2178, 2003.
18. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644, 2009.
19. Granville CA, Memmott RM, Gills JJ and Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12:679-689, 2006.
20. Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192, 2006.
21. Markman B, Atzori F, Perez-Garcia J, Tabernero J and Baselga J: Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21:683-691, 2010.
22. Yuan R, Kay A, Berg WJ and Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45, 2009.
23. Li H, Zhao L, Yang Z, Funder JW and Liu JP: Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem 273:33436-33442, 1998.
24. Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274:13085-13090, 1999.
25. Kim JH, Park SM, Kang MR, et al: Ubiquitin ligase MKRN 1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 19:776-781, 2005.
26. Karamitopoulou E: Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol 2:209, 2013.
27. Liu Z, Li Q, Li K, et al: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32:4203-4213, 2013.
28. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458, 2003.
29. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273:114-127, 2013.
30. Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51, 2011.
31. Sasaki T, Kuniyasu H, Luo Y, et al: AKT activation and telomerase reverse transcriptase expression are concurrently associated with prognosis of gastric cancer. Pathobiology 81:36-41, 2014.
32. Sasaki T, Kuniyasu H, Luo Y, et al: Increased phosphorylation of AKT in high-risk gastric mucosa. Anticancer Res 33:3295-3300, 2013.